C-MET Metastatic NSCLC Market: Epidemiology, Therapies, Companies, DelveInsight | Novartis, Merck, EMD Serono, AbbVie, Regeneron Pharmaceuticals, Mythic Therapeutics, Apollomics, Johnson & Johnson Innovation, Haihe Biopharma

C-MET Metastatic NSCLC therapies, such as TABRECTA, TEPMETKO, Telisotuzumab Vedotin, REGN5093, REGN5093-M114, APL-101, MYTX-011, Glumetinib, Amivantamab and Capmatinib Combination Therapy, and others, are expected to boost the C-MET Metastatic NSCLC Market in the upcoming years.

DelveInsight has launched a new report on "C-MET Metastatic NSCLC - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the C-MET Metastatic NSCLC, historical and forecasted epidemiology as well as the C-MET Metastatic NSCLC market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the C-MET Metastatic NSCLC market report @ https://www.delveinsight.com/report-store/cmet-mnsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the C-MET Metastatic NSCLC Market Report:

The total c-MET metastatic NSCLC market size across the seven major markets (7MM) was estimated at around USD 590 million in 2023 and is expected to grow with the introduction of new therapies. The U.S. dominated the market, accounting for roughly 75% of the total value.
In May 2025, the FDA granted accelerated approval to telisotuzumab vedotin, branded as Emrelis by AbbVie, for adults with locally advanced or metastatic non-squamous NSCLC exhibiting high c-Met protein overexpression (≥50% of tumor cells with strong staining), who have received prior systemic therapy. This approval was supported by data from the Phase II LUMINOSITY trial, which demonstrated a 35% overall response rate in patients with high c-Met expression. The FDA also approved the VENTANA MET (SP44) RxDx assay as a companion diagnostic to identify eligible patients for Emrelis therapy.
In 2023, there were approximately 524,000 new cases of non-small cell lung cancer (NSCLC) reported across the seven major markets (7MM), and this number is expected to rise over the forecast period. In the United States alone, NSCLC accounted for around 202,500 new cases that same year.
TABRECTA (capmatinib) and TEPMETKO (tepotinib) are two FDA-approved small-molecule inhibitors targeting MET exon 14 skipping mutations, offering significant treatment options for NSCLC patients with MET alterations. TABRECTA is likely to retain its lead in this space due to its early market entry.
In May 2024, early findings from the METalmark trial showed that the combination of amivantamab and TABRECTA demonstrated encouraging safety and efficacy in advanced MET-driven NSCLC, with the Phase II recommended dose established.
In 2023, off-label use of crizotinib and other targeted therapies made up about USD 100 million of the U.S. c-MET NSCLC market, while TABRECTA generated approximately USD 200 million.
However, TABRECTA was withdrawn from the German market due to challenges with the AMNOG health technology assessment system. In February, the G-BA concluded that there was no proven additional benefit of TABRECTA for certain advanced NSCLC patients. Supplies are expected to last until March 2024, after which access will be limited to named patient programs requiring insurer approval.
While MET alterations are key targets in NSCLC, current MET TKIs, antibody therapies, and antibody-drug conjugates still face opportunities for advancement despite their anticancer activity.
Key C-MET Metastatic NSCLC companies such as Novartis, Merck, EMD Serono, AbbVie, Regeneron Pharmaceuticals, Mythic Therapeutics, Apollomics, Johnson & Johnson Innovation, Haihe Biopharma, and others are evaluating new drugs for C-MET Metastatic NSCLC to improve the treatment landscape.
Promising C-MET Metastatic NSCLC therapies include TABRECTA, TEPMETKO, Telisotuzumab Vedotin, REGN5093, REGN5093-M114, APL-101, MYTX-011, Glumetinib, Amivantamab and Capmatinib Combination Therapy, and others.

C-MET Metastatic NSCLC Overview

Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, making up about 85% of all cases. It is primarily divided into adenocarcinomas, squamous cell carcinomas, and large cell carcinomas, with rarer forms like adenosquamous and sarcomatoid carcinomas also included.

The MET gene, located on chromosome 7q31.2, encodes the c-Met receptor-a transmembrane tyrosine kinase. In healthy epithelial cells, c-Met is expressed at low levels, but its expression can increase significantly-by 2 to 50 times-in various cancers such as NSCLC, renal cell carcinoma, colorectal cancer, and liver cancer.

C-MET inhibitors have shown anti-cancer activity in NSCLC in both lab and clinical settings. However, because of NSCLC's genetic complexity, these therapies are likely effective only in a specific subgroup of patients.

C-MET Metastatic NSCLC Market Outlook

Historically, research into MET as an oncogenic driver in NSCLC focused mainly on MET gene amplification, which is present in a small subset of patients. Earlier findings suggested that targeting MET amplification with specific drugs might offer therapeutic benefits. However, more recent studies have identified that a larger proportion of NSCLC patients harbor MET mutations-particularly alterations that result in MET exon 14 skipping. These mutations impair the normal degradation of the MET protein, allowing it to accumulate and drive tumor growth. This MET exon 14 skipping has now been recognized as a key driver in about 3-4% of NSCLC cases.

Currently, two MET tyrosine kinase inhibitors (TKIs)-TABRECTA and TEPMETKO-are approved worldwide for treating MET exon 14-altered NSCLC. In China, savolitinib is the only approved MET inhibitor. Additional treatment options may include enrollment in clinical trials for novel MET-targeting agents, immunotherapy with or without chemotherapy, or the off-label use of crizotinib.

For NSCLC patients without known driver mutations, the standard first-line treatment typically includes platinum-based chemotherapy or immune checkpoint inhibitors (ICIs), alone or in combination, guided by PD-L1 expression levels and patient condition. In second-line settings, ICIs may be used as monotherapy if not previously administered. For patients with actionable oncogenic drivers, targeted therapies are the preferred option, as standard treatments tend to be less effective in tumors driven by specific genetic alterations.

Discover how the C-MET Metastatic NSCLC market is rising in the coming years @ https://www.delveinsight.com/sample-request/cmet-mnsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

C-MET Metastatic NSCLC Marketed Drugs
TABRECTA (capmatinib): Novartis
TEPMETKO (tepotinib): EMD Serono/Merck KGaA

C-MET Metastatic NSCLC Emerging Drugs
Telisotuzumab Vedotin: AbbVie
REGN5093 and REGN5093-M114: Regeneron Pharmaceuticals

Scope of the C-MET Metastatic NSCLC Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key C-MET Metastatic NSCLC Companies: Novartis, Merck, EMD Serono, AbbVie, Regeneron Pharmaceuticals, Mythic Therapeutics, Apollomics, Johnson & Johnson Innovation, Haihe Biopharma, and others
C-MET Metastatic NSCLC Therapeutic Assessment: C-MET Metastatic NSCLC current marketed and C-MET Metastatic NSCLC emerging therapies
C-MET Metastatic NSCLC Market Dynamics: C-MET Metastatic NSCLC market drivers and C-MET Metastatic NSCLC market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
C-MET Metastatic NSCLC Unmet Needs, KOL's views, Analyst's views, C-MET Metastatic NSCLC Market Access and Reimbursement

To know what's more in our C-MET Metastatic NSCLC report, visit https://www.delveinsight.com/report-store/cmet-mnsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the C-MET Metastatic NSCLC Market Report:
C-MET Metastatic NSCLC market report covers a descriptive overview and comprehensive insight of the C-MET Metastatic NSCLC Epidemiology and C-MET Metastatic NSCLC market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The C-MET Metastatic NSCLC market report provides insights into the current and emerging therapies.
The C-MET Metastatic NSCLC market report provides a global historical and forecasted market covering drug outreach in 7MM.
The C-MET Metastatic NSCLC market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the C-MET Metastatic NSCLC market.

Got queries? Click here to know more about the C-MET Metastatic NSCLC market Landscape https://www.delveinsight.com/sample-request/cmet-mnsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. C-MET Metastatic NSCLC Patient Share (%) Overview at a Glance
5. C-MET Metastatic NSCLC Market Overview at a Glance
6. C-MET Metastatic NSCLC Disease Background and Overview
7. C-MET Metastatic NSCLC Epidemiology and Patient Population
8. Country-Specific Patient Population of C-MET Metastatic NSCLC
9. C-MET Metastatic NSCLC Current Treatment and Medical Practices
10. Unmet Needs
11. C-MET Metastatic NSCLC Emerging Therapies
12. C-MET Metastatic NSCLC Market Outlook
13. Country-Wise C-MET Metastatic NSCLC Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. C-MET Metastatic NSCLC Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about C-MET Metastatic NSCLC Market Outlook 2034 https://www.delveinsight.com/report-store/cmet-mnsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

C-MET Metastatic NSCLC Pipeline Insights, DelveInsight

"C-MET Metastatic NSCLC Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the C-MET Metastatic NSCLC market. A detailed picture of the C-MET Metastatic NSCLC pipeline landscape is provided, which includes the disease overview and C-MET Metastatic NSCLC treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.